How Did Medtronic Fare In Q4’16 Earnings?
Leading medical device maker Medtronic (NYSE:MDT) posted its Q4’16 earnings on May 31st. (Fiscal years end with April.) The company got FDA approval during the quarter for its Micra transcatheter system, the world’s smallest pacemaker. We expect Medtronic to see growth in the next fiscal year to come from the adoption of its Micra pacemaker in the U.S. We alos foresee market share gains from the MRI-safe pacemakers and defibrillators, and the and the adoption of its Visia ICD in the Europe. Below we show the key metrics and expected future trends for the company, based on Q4’16 results:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)
- What’s Next For Medtronic Stock After An Upbeat Q3?
- Up Just 6% In 2023 Is Medtronic Stock A Better Pick Over Abbott?
- Should You Pick Medtronic Stock At $80 After An Upbeat Q2?
- After A 6% Rise This Month Should You Pick Medtronic Stock Ahead of Its Q2?
- Should You Buy Medtronic Stock After A Q1 Beat?
- Will Medtronic Stock Rebound To Its Pre-Inflation Shock Highs?